BTIG has initiated coverage on Maze Therapeutics Inc (MAZE) with a Buy rating, marking the firm's first assessment of the company. This decision underscores BTIG's confidence in Maze's potential within the pharmaceutical industry, particularly as it focuses on developing precision medicines for renal, cardiovascular, and related metabolic diseases.
Maze Therapeutics, headquartered in South San Francisco, California, is a clinical-stage biopharmaceutical company leveraging human genetics to create novel small-molecule treatments. The firm employs 125 full-time staff and went public on January 31, 2025. Its flagship programs, MZE829 and MZE782, are designed to address chronic kidney disease (CKD) through innovative approaches.
As of now, Maze Therapeutics has a market capitalization of $1.4 billion and reported an EPS of -0.59 (TTM). The company is set to announce its next earnings on November 6, 2025, with an estimated EPS of -0.72 and projected revenue of $0.
The analyst consensus currently stands at a Buy, with 5 Strong Buy, 6 Buy, and 1 Hold ratings from a total of 12 analysts. Recent analyst actions include BTIG's initiation on September 2, 2025, following similar ratings from HC Wainwright & Co. and Wedbush earlier this year.
Such analyst ratings provide valuable insights but should be considered alongside other factors like company fundamentals and market conditions as investors make decisions.